Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons

Journal of Neuroscience Research

Volumn 91, Issue 12, 2013, Pages 1609-1617

  Ballaz, Santiago ^a,b   Morales, Ingrid ^b,c   Rodríguez, Manuel ^b,c   Obeso, José A ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

AMPA receptor; Glutamate metabotropic receptors; Kainate receptor; NMDA receptor; Parkinson's disease; SH SY5Y

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; ANTIOXIDANT; ASCORBIC ACID; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GLUTAMIC ACID; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPROTECTIVE AGENT; PROTEIN P53; QUERCETIN; TAU PROTEIN; VESICULAR MONOAMINE TRANSPORTER 2;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; FENTON REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM EXPOSURE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; WESTERN BLOTTING;

AMPA RECEPTOR; GLUTAMATE METABOTROPIC RECEPTORS; KAINATE RECEPTOR; NMDA RECEPTOR; PARKINSON'S DISEASE; SH-SY5Y;

ANTIOXIDANTS; ASCORBIC ACID; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DOPAMINERGIC NEURONS; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 84886641494     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23276     Document Type: Article

References (62)

1. Avshalumov MV, Patel JC, Rice ME. 2008. AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not dopamine axons: one source of a retrograde signal that can inhibit dopamine release. J Neurophysiol 100:1590-1601.
2. Battaglia G, Busceti CL, Pontarelli F, Biagioni F, Fornai F, Paparelli A, Bruno V, Ruggieri S, Nicoletti F. 2003. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Neuropharmacology 45:155-166.
3. Blandini F, Porter RH, Greenamyre JT. 1996. Glutamate and Parkinson's disease. Mol Neurobiol 12:73-94.
4. Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, Haenen GR. 2007. The quercetin paradox. Toxicol Appl Pharmacol 222:89-96.
5. Borland MK, Trimmer PA, Rubinstein, JD, Keeney PM, Mohanakumar K, Liu L, Bennett JP Jr. 2008. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener 3:21. doi: 10.1186/1750-1326-3-21.
6. Boulter J, Hollmann M, O'Shea-Greenfield A, Hartley M, Deneris E, Maron C, Heinemann S. 1990. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249:1033-1037.
7. Caprile T, Salazar K, Astuya A, Cisternas P, Silva-Alvarez C, Montecinos H, Millán C, de Los Angeles García M, Nualart F. 2009. The Na+-dependent L-ascorbic acid transporter SVCT2 expressed in brainstem cells, neurons, and neuroblastoma cells is inhibited by flavonoids. J Neurochem 108:563-577.
8. Chaudière J, Ferrari-Iliou R. 1999. Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem Toxicol 37:949-962.
9. Choi DW. 1992. Excitotoxic cell death. J Neurobiol 23:1261-1276.
10. Counihan TJ, Landwehrmeyer GB, Standaert DG, Kosinski CM, Scherzer CR, Daggett LP, Veliçelebi G, Young AB, Penney JB Jr. 1998. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons. J Comp Neurol 390:91-101.
11. Dorsey DA, Mascó DH, Dikranian K, Hyrc K, Masciotra L, Faddis B, Soriano M, Gru AA, Goldberg MP, de Erausquin GA. 2006. Ultrastructural characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced cell death in embryonic dopaminergic neurons. Apoptosis 11:535-544.
12. Etminan M, Gill SS, Samii A. 2005. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 4:362-365.
13. Fahn S. 1991. An open trial of high-dosage antioxidants in early Parkinson's disease. Am J Clin Nutr 53(Suppl 1):380S-382S.
14. Gao M, Zhang WC, Liu QS, Hu JJ, Liu GG, Du GH. 2008. Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of Bax/bcl-2 ratio. Eur J Pharmacol 591:73-79.
15. Halliwell B, Clement MV, Ramalingam J, Long LH. 2000. Hydrogen peroxide. Ubiquitous in cell culture and in vivo? IUBMB Life 50:251-257.
16. Hansen J, Bross P. 2010. A cellular viability assay to monitor drug toxicity. Methods Mol Biol 648:303-311.
17. Harrinson FE, May J. 2009. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 46:719-730.
18. Herrera F, Sainz RM, Mayo JC, Martín V, Antolín I, Rodriguez C. 2001. Glutamate induces oxidative stress not mediated by glutamate receptors or cystine transporters: protective effect of melatonin and other antioxidants. J Pineal Res 31:356-362.
19. Hu Y, Li J, Liu P, Chen X, Guo DH, Li QS, Rahman K. 2012. Protection of SH-SY5Y neuronal cells from glutamate-induced apoptosis by 3, 6′-disinapoyl sucrose, a bioactive compound isolated from Radix polygala. J Biomed Biotechnol doi:10.1155/2012/728342.
20. Jalava A, Heikkilä J, Akerman K, Påhlman S. 1992. Staurosporine induces a neuronal phenotype in SH-SY5Y human neuroblastoma cells that resembles that induced by the phorbol ester 12-O-tetradecanoyl phorbol-13 acetate (TPA). FEBS Lett 300:114-118.
21. Jankovic J, Hunter C. 2002. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Rel Disord 8:271-276.
22. Jenner P, Olanow CW. 1992. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47:S161-S170.
23. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32:S82-S87.
24. Kashino G, Kodama S, Nakayama Y, Suzuki K, Fukase K, Goto M, Watanabe M. 2003. Relief of oxidative stress by ascorbic acid delays cellular senescence of normal human and Werner syndrome fibroblast cells. Free Radic Biol Med 35:438-443.
25. Khan S, Jyoti S, Naz F, Shakya B, Afzal M, Siddique YH. 2012. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. Int J Neurosci 122:704-709.
26. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. 1993. NMDA-dependent superoxide production and neurotoxicity. Nature 364:535-537.
27. Levy G. 2007. The relationship of Parkinson disease with aging. Arch Neurol 64:1242-1246.
28. Li X, Huang JH, May JM. 2003. Ascorbic acid spares α-tocopherol and decreases lipid peroxidation in neuronal cells. Biochem Biophys Res Commun 305:656-661.
29. Lopes FM, Schröder R, da Frota ML Jr, Zanotto-Filho A, Müller CB, Pires AS, Meurer RT, Colpo GD, Gelain DP, Kapczinski F, Moreira JC, Fernandes Mda C, Klamt F. 2010. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res 1337:85-94.
30. Maher P, Davis JB. 1996. The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 16:6394-6401.
31. Majewska MD, Bell JA. 1990. Ascorbic acid protects neurons from injury induced by glutamate and NMDA. Neuroreport 1:194-196.
32. May JM, Li L, Hayslett K, Qu ZC. 2006. Ascorbate transport and recycling by SH-SY5Y neuroblastoma cells: response to glutamate toxicity. Neurochem Res 31:785-794.
33. Metodiewa D, Jaiswal AK, Cenas N, Dickancaité E, Segura-Aguilar J. 1999. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med 26:107-116.
34. Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M. 2011. Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur J Neurol 18:106-113.
35. Monaghan DT, Bridges RJ, Cotman CW. 1989. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365-402.
36. Morales I, Fuentes A, Ballaz S, Obeso JA, Rodríguez M. 2012. Striatal interactions among dopamine, glutamate, and ascorbic acid. Neuropharmacology 63:1308-314.
37. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:53-63.
38. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. 2004. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121:60-69.
39. Naarala J, Nykvist P, Toumala M, Savolainen K. 1993. Excitatory amino acid-induced slow biphasic responses of free intracellular calcium in human neuroblastoma cells. FEBS Lett 330:222-226.
40. Naoi M, Maruyama W. 1999. Cell death of dopamine neurons in aging and Parkinson's disease. Mech Ageing Dev 111:175-188.
41. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G. 2010. Missing pieces in the Parkinson's disease puzzle. Nat Med 16:653-661.
42. Przedborski S. 2005. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Rel Disord Suppl 1:S3-S7.
43. Qiu S, Li L, Weeber EJ, May JM. 2007. Ascorbate transport by primary cultured neurons and its role in neuronal function and protection against excitotoxicity. J Neurosci Res 85:1046-1056.
44. Rebec GV, Barton SJ, Marseilles AM, Collins K. 2003. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14:1263-1265.
45. Rebec GV, Witowski SR, Sandstrom MI, Rostand RD, Kennedy RT. 2005. Extracellular ascorbate modulates cortically evoked glutamate dynamics in rat striatum. Neurosci Lett 378:166-170.
46. Rice ME. 2000. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci 23:209-216.
47. Rodriguez MC, Obeso JA, Olanow CW. 1998. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44(Suppl 1):S175-S188.
48. Rodriguez M, Sabate M, Rodriguez-Sabate C, Morales I. 2013. The role of non-synaptic extracellular glutamate. Brain Res Bull 93:17-26.
49. Sato H, Tamba M, Ishii T, Bannai S. 1999. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274:11455-11458.
50. Schapira AH. 2008. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7:97-109.
51. Schiemann J, Schlaudraff F, Klose V, Bingmer M, Seino S, Magill PJ, Zaghloul KA, Schneider G, Liss B, Roeper J. 2012. K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. Nat Neurosci 15:1272-1280.
52. Sun Z, Zhang L, Zhu S, Chen W, Mei B. 2010. Excitotoxic effects of glutamate on human neuroblastoma SH-SY5Y cell via oxidative damage. Neurosci Bull 26:8-16.
53. Tang WX, Fasulo WH, Mash DC, Hemby SE. 2003. Molecular profiling of midbrain dopamine regions in cocaine overdose victims. J Neurochem 85:911-924.
54. Tetich M, Kutner A, Leskiewicz M, Budziszewska B, Lason W. 2004. Neuroprotective effects of (24R)-1, 24-dihydroxycholecalciferol in human neuroblastoma SH-SY5Y cell line. J Steroid Biochem Mol Biol 89-90:365-370.
55. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. 1991. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418.
56. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. 1996. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46:1551-1556.
57. Wagner GC, Jarvis MF, Carelli RM. 1985. Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology 24:1261-1262.
58. Wang M, Li S, Zhang H, Pei L, Zou S, Lee FJ, Wang YT, Liu F. 2012. Direct interaction between GluR2 and GAPDH regulates AMPAR-mediated excitotoxicity. Mol Brain 5:13.
59. Weber CA, Ernst ME. 2006. Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 40:935-938.
60. Xie H, Hu L, Li G. 2010. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J 123:1086-1092.
61. Yapa SC. 1992. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health 106:393-395.
62. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. 2002. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161-1169.